BIRC2, BIRC3 and TRAF3 proteins all interact directly with NIK, suppressing NFκB-pathway activity.(25) MM cell lines with deletions of BIRC2/BIRC3 or TRAF3, predominantly t(4;14), have high NIK levels and activated NFκB-pathway signalling, as demonstrated by Keats et al. Recently, specific NIK inhibitors have been developed which might be used to target high-risk t(4;14) MM.26, 27, 28 Virtually all BIRC2/3 deletions were found in FGFR3-positive tumors. The gene discussed is BIRC2; the disease is Miyoshi myopathy.